The "Leaves" of the OSP Suite





Outline

- Vision and Mission of the OSP
- The OSP Community Landscape
 - OSP MT, Focus Groups and Users
- Intra- & Extra-Community Collaboration
- Sprouting Leaves
- Food for Thought



Vision and Mission of the OSP





Vision and Mission of the OSP

https://github.com/Open-Systems-Pharmacology/Roadmap

Robust and reliable, easy-to-use modeling & simulation tools, processes and models for pharmaceutical and other life-sciences applications qualified and accepted by a scientific community from academia, regulatory agencies and industry available and open to everyone.

Provide a platform for joint development, review & qualification, and application of state-of-the-art tools for PBPK and Systems Pharmacology modeling and an open library of models for application as well as method & tool qualification purposes. Promote the idea of pre-competitive open collaboration for the advancement of modeling & simulation sciences in pharmaceutical and life science.



The OSP Community Landscape








The OSP Community Landscape

Stakeholders of the Open Systems Pharmacology community and Management Team





The OSP Community Landscape

Stakeholders of the Open Systems Pharmacology community and Management Team

Dedicated Focus Groups have been established to conceptualize, design and progress the individual areas, the Management Team will coordinate the interplay of focus areas and interfaces between them


Focus groups shall be the owner of the development in the respective focus area, they are expected to conceptualize and coordinate activities of the respective field.

•	DDI Special Populations Absorption	DDI	Quantitative DDI predictions (CYPs as well as transporters) are one of the key applications for PBPK and are a prerequisite for designing efficient clinical development programs and studies. A comprehensive library of well documented, qualified perpetrators and victims is a prerequisite for acceptance of DDI predictions from regulatory authorities.	Sebastian Frechen (@sfrechen)	
•	PD Statistical modelling First in Human (IVIVE) Omics	IVIVE	 Improve and facilitate use of IVIVE in PK-Sim Provide guidelines on how to conduct IVIVE in PK-Sim Facilitate integration of in vitro data in prediction of DDI (e.g. integration of fraction metabolized) Extrapolation of Caco-2 permeabilities to effective permeabilities 	Donato Teutonico <u>(@teutonicod)</u>	
•	Suite Release Management Automation/Qualification Community Engagement (PR) Biologics Nonclinical PBPK	Special populations	 The addition of new or updated virtual populations is required to expand the application scope of the software in a consistent manner across users. The overall objectives are to define a process for 1. technical generation of populations destined for the OSP Suite and, 2. evaluation of those populations. This protocol will allow populations to be added more efficiently. 	Andrea Edginton <u>(@Aedginto)</u>	
•	PBBM HT PBPK	Statistical Modelling	Statistical Modeling is a strategic theme of the OSP MT. Statistical modeling is a key enabler for PBPK and QSP M&S. Respective capabilities are required for all application areas to quantitatively	Christian Diedrich (@DiedrichC)	0 P



The OSP Community Landscape

User Community: Forum: github.com/Open-Systems-Pharmacology/Forum





Community Collaboration(s)







Community Collaboration(s)



Editor's Choice: Original Article 🔂 Open Access 💿 💽 😒


In-Depth Analysis of the Selection of PBPK Modeling Tools: Bibliometric and Social Network Analysis of the Open Systems Pharmacology Community

André Dallmann PhD 🔀, Donato Teutonico PhD, Stephan Schaller PhD, Rolf Burghaus PhD, Sebastian Frechen MD






Community Collaboration(s)



GSP OPEN SYSTEMS PHARMACOLOGY



Community Collaboration(s)




"Sprouting Leaves"











Sprouting Leaves Chemical Risk Assessment



Archives of Toxicology https://doi.org/10.1007/s00204-024-03764-9


IN SILICO

Systematic evaluation of high-throughput PBK modelling strategies for the prediction of intravenous and oral pharmacokinetics in humans

René Geci^{1,2}[®] · Domenico Gadaleta³ · Marina García de Lomana⁴ · Rita Ortega-Vallbona⁵ · Erika Colom Eva Serrano-Candelas⁵ · Alicia Paini¹ · Lars Kuepfer² · Stephan Schaller¹

• PBK simulations for more than 200 chemicals for IV and oral exposure scenarios in humans and compared to *in vivo* data in the literature.

Systematically tested different parameterization strategies.








Sprouting Leaves





"Food for Thought" How to Continue from here





Regulatory Submissions with PK-Sim

OSP file formats are added to FDA's white list of file formats for electronic submissions

The following OSP file formats are included:

- •.pksim5 (PK-Sim project file)
- •.mbp3 (MoBi project file)
- •.pkml (OSP model exchange format)
- •.json (PK-Sim project snapshots file)

Specifications for File Format Types Using eCTD Specifications

Revision History

Date	Version	Summary of Changes
2023-12-01	9.0	Updated .docx permissible uses Updated .xml accepted locations and permissible uses Removed "CDER Only" from permissible uses for: .csv, .cas, .dat, .rmd, .r Updated file format added: Modeling & Simulation file types: .pksim5, .mbp3, .pkml, .json .mlxtran, .mlxproperties, .pkx, .pkxproperties, smlx, .smlxproperties, .syc, .datxplore





Food for Thought



Think about what you learn

 \rightarrow Think about what you are still missing (Free Feedback)



